Get 50% OFF This Summer!

Advertisement
AdvertisementAdvertisement
logo

Venus Remedies

VENUSREM
Micro Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Venus Remedies Share price and Fundamental Analysis

View All Details
View All Details
Incorporated in 1989 Venus Remedies Ltd (formerly known Venus Glucose Pvt Ltd), was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited. The Company was promoted and managed by Chaudhary & Family. The Company is one of the handful player in pharmaceutical sector to launch injectables globally. It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India). In priority, the Company was mainly engaged in I/V Fluids & Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc.
Company Incorporation1989
ChairmanPawan Chaudhary
Head QuartersPanchkula
Previous NameNA

Key Metrics

Market Cap (Cr)
474.39
PE Ratio
17.02
Industry P/E
53.03
PEG Ratio
-4.28
ROE
4.47%
ROCE
7.72%
ROA
5.28%
Total Debt (Cr)
40.91
Debt to Equity
0.08
Dividend Yield
0%
EPS
20.85
Book Value & P/B
369.73 x 0.96
Face Value
10
Outstanding Shares(Cr)
1.34
Current Ratio
3.96
EV to Sales
0.67

Stock Returns

1 Week+8.7%
1 Month+4.52%
6 Months+20.1%
1 Year+19.57%
3 Years+59.38%
5 Years+613.93%

CAGR

1 Year CAGR

Revenue Growth

+8.27%

Net Profit Growth

+7.25%

Operating Profit Growth

+0.93%

Dividend Growth

N/A

Stock Returns CAGR

+19.67%
no_data

No Stocks

Smart Score

2.3
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone
PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 41.76%

FIIs : 1.34%

DIIs : 0.00%

Public : 56.90%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
FII Shareholding Increased by 0.23% to 1.34% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Venus Remedies Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Venus Remedies Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Incorporated in 1989 Venus Remedies Ltd (formerly known Venus Glucose Pvt Ltd), was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited. The Company was promoted and managed by Chaudhary & Family. The Company is one of the handful player in pharmaceutical sector to launch injectables globally. It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India). In priority, the Company was mainly engaged in I/V Fluids & Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc.

The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana. In 1994 it introduced Eye/Ear/Nose drops. The company received the certificate as 'WHO-GMP' as specified by WHO,Geneva. Venus Remedies set up a Cephalosporin project with an Australian collaboration with US-FDA standards at a cost of Rs.4.5 crores. The company is manufacturing injections for the top companies like Panacea Biotech ltd,Morepan Labortories ltd etc.

In 2001 with the help of Product Development Committee(PDC) Venus Remedies had introduced 13 new products in the Animal Health Division namely Megox-3000,Paroxin-3000,Pisa-3000,Mical,Ronid,Dexolyte and Detox.

The year 2005-06 saw many new milestone achievements by the Company like commercial operation of its most modern and techno-savvy manufacturing unit at Baddi, formation of a WOS in Germany and acquisition of a running, German-GMP certified pharmaceutical unit at Werne, Germany, launch of its second R&D Product after DCGI Approval etc. There was a rigorous activity for development on all fronts and the Company made huge investments in projects at Panchkula, Baddi and now at Werne, Germany for renovations, new Projects and acquisition as well.

The Company was the first to launch Injection Meropenem in Paediatric Dosage of 125 mg in its Domestic Marketing during the year 2006-07. It further launched fourth research product, a fixed dose combination of cephalosporin with aminoglycoside under the 'Tobracef' brand in 2008-09. It launched its anti-cancer drug 'Docetaxel' in Europe by end 2011, launched ACHNIL, the once-a-day pain management therapy in India in 2011; launched 'Cytomib', a first-time therapy against blood cancer in 2011; launched 'Taxedol' in three strengths-20 mg, 80 mg and 120 mg in 2012.

In 2013, the Company established pre-clinical proof of concept for its Drug -Protein-Polymer- Conjugate (DPPC); introduced Ready-to-Use a Single Vial Taxedol in India; launched 'Trois', a miracle nano-emulsion for arthritic Pain; launched 'Elores' - CSE 1034, a US patent protected product in India, launched its first OTC product 'Ezenus'.

In 2014, the Company launched ELORES, an antibiotic to fight superbugs'. In 2021-22, it launched first product in the consumer healthcare space, R3SET - a Pain Management solution. Besides this, Venpocare dealing with Wound Healing was also launched during year 2022. To make internal processes smart and streamlined, many solutions including an automated order processing system, retail billing system, new warehouse (VFC) with barcode automation, etc. were launched. For quicker and more effective decision-making, a BI tool like Tableau was also launched in 2022.

Venus Remedies Share Price

Venus Remedies share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Venus Remedies Market Cap

Market capitalization of Venus Remedies indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Venus Remedies is valued compared to its competitors.

Venus Remedies PE Ratio

Venus Remedies PE ratio helps investors understand what is the market value of each stock compared to Venus Remedies 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Venus Remedies PEG Ratio

The PEG ratio of Venus Remedies evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Venus Remedies ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Venus Remedies generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Venus Remedies ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Venus Remedies in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Venus Remedies Total Debt

Total debt of Venus Remedies shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Venus Remedies Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Venus Remedies compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Venus Remedies CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Venus Remedies over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Venus Remedies Technical Analysis

Technical analysis of Venus Remedies helps investors get an insight into when they can enter or exit the stock. Key components of Venus Remedies Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Venus Remedies shares often struggle to rise above due to selling pressure.

Venus Remedies Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Venus Remedies ’s financial health and profitability.

Venus Remedies Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Venus Remedies Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Venus Remedies Financials

The financials of Venus Remedies provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Venus Remedies Profit and Loss Statements

The profit and loss statement of Venus Remedies highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Venus Remedies .

Venus Remedies Balance Sheet

The balance sheet presents a snapshot of Venus Remedies ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Venus Remedies Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App

Download the App